TrialAlzheimer's research & therapy2018

Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY).

Elizabeth Finger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.